(Q43265336)

17 November 2017

Attacking cancer at its foundation (English)

1 reference

17 November 2017

Nicholas Lydon

1

1 reference

PubMed ID

19812577

17 November 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

15

1 reference

17 November 2017

1153-1157

1 reference

17 November 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nm1009-1153

17 November 2017

0 references

cites work

Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM1009-1153

Selecting the right patient for tumor therapy

21 January 2018

1 reference

12 December 2020

Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors

1 reference

12 December 2020

Protein kinases--the major drug targets of the twenty-first century?

1 reference

12 December 2020

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

12 December 2020

Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity

1 reference

12 December 2020

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

12 December 2020

Gefitinib--a novel targeted approach to treating cancer

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Oncogenic kinase signalling

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

12 December 2020

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

A TRANSMISSIBLE AVIAN NEOPLASM. (SARCOMA OF THE COMMON FOWL.)

1 reference

12 December 2020

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

The Proteins of Oncogenes

1 reference

12 December 2020

Regulation of protein kinases activity by quercetin in Ehrlich ascites tumor cells

1 reference

12 December 2020

Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus

1 reference

12 December 2020

A quantitative analysis of kinase inhibitor selectivity

1 reference

12 December 2020

Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction

1 reference

12 December 2020

Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.

1 reference

12 December 2020

An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase.

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

The conformational plasticity of protein kinases

1 reference

12 December 2020

The protein kinase family: conserved features and deduced phylogeny of the catalytic domains

1 reference

12 December 2020

Simian Sarcoma Virus onc Gene, v- sis , Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth Factor

1 reference

12 December 2020

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).

1 reference

12 December 2020

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus

1 reference

12 December 2020

Imatinib: a review of its use in the management of gastrointestinal stromal tumours

1 reference

12 December 2020

Rational design of inhibitors that bind to inactive kinase conformations

1 reference

12 December 2020

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

12 December 2020

Oncogenes, growth factors, and signal transduction

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

A thousand and one protein kinases

1 reference

12 December 2020

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

1 reference

12 December 2020

Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3

1 reference

12 December 2020

High-throughput kinase profiling as a platform for drug discovery

1 reference

12 December 2020

ZD6474--clinical experience to date

1 reference

12 December 2020

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

12 December 2020

Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase

1 reference

12 December 2020

Transforming gene product of Rous sarcoma virus phosphorylates tyrosine

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM1009-1153

1 reference

17 November 2017

1 reference

PubMed ID

19812577